Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Excerpt
The Canadian Agency for Drugs and Technologies in Health (CADTH) will undertake a systematic review to compare the efficacy and safety of disease-modifying agents for patients with relapsing-remitting multiple sclerosis (RRMS), and will examine their cost-effectiveness. The review will include disease-modifying agents that are currently available in Canada (interferon beta-1a and -1b, natalizumab, glatiramer acetate, fingolimod), and a number of agents that are newly emerging and not yet approved in Canada (teriflunomide, dimethyl fumarate, and alemtuzumab).
The systematic review and cost-effectiveness evidence will be reviewed by the Canadian Drug Expert Committee (CDEC) for the purpose of making recommendations. Recommendations and advice provided by CDEC are provided to CADTH to inform participating jurisdictions.
Contents
This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). This report contains a comprehensive review of existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time it was prepared, and it was guided by expert input and advice throughout its preparation.
The information in this report is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this report to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report. CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government.
Production of this report is made possible through a financial contribution from Health Canada.
- NLM CatalogRelated NLM Catalog Entries
- Review Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis[ 2013]Review Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis. 2013 Oct
- Review Drugs for Pulmonary Arterial Hypertension — Project Protocol[ 2014]Review Drugs for Pulmonary Arterial Hypertension — Project Protocol. 2014 Feb
- Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review.[Farm Hosp. 2020]Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review.Navarro CE, Ordóñez-Callamand E, Alzate JP. Farm Hosp. 2020 Mar 1; 44(2):68-76. Epub 2020 Mar 1.
- Review Established disease-modifying treatments in relapsing-remitting multiple sclerosis.[Curr Opin Neurol. 2015]Review Established disease-modifying treatments in relapsing-remitting multiple sclerosis.Oh J, O'Connor PW. Curr Opin Neurol. 2015 Jun; 28(3):220-9.
- Review Medicines Used for Multiple Sclerosis – A Health Technology Assessment[ 2016]Review Medicines Used for Multiple Sclerosis – A Health Technology AssessmentCouto E, Hamidi V, Ringerike T, Odgaard-Jensen J, Harboe I, Klemp M. 2016 Feb
- Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remi...Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis — Project Protocol
Your browsing activity is empty.
Activity recording is turned off.
See more...